Christophe Beck
Chairman & Chief Executive Officer at Ecolab
Thank you so much, Andy, and welcome to everyone. Look, our team delivered another strong quarter. Once again, even slightly better than I would have predicted. Topline was very strong, volume trends remained stable, margins expanded, operating income growth got even stronger and adjusted EPS growth kept improving as we promised. All as promised, as we continued to face some real headwinds in foreign exchange and interest. Most importantly, our shift to offense showed some real encouraging signs of progress.
Organic sales improved from 12% in the fourth quarter to 13% in the first, with strong performance across all segments. Our net new business pipeline once again reached new records in the first quarter, as what we have to offer water, energy and labor savings while delivering the best and safest outcomes in the industries we serve continues to grow in importance for our customers.
We also maintained very strong pricing at 13%, which we believe will be the peak as we will begin to lap against last year's strong acceleration. Our approach to pricing and it's important to state that is responsible and respectful, allowing our customers to absorb long-term increases in a progressive manner. This is backed by true eROI value, the Ecolab way, as we help them reduce the overall operating costs, usage of natural resources and their environmental impact.
Delivered product cost continued to increase versus last year, but the rate of inflation began to ease. This along with strong pricing execution allowed us to drive modest gross margin expansion a bit earlier than expected. That being said, our margin recovery journey has only just begun. Despite our expectation that inflation remained stubbornly high, we remain fully committed to recovering our margin over time. Done the right way, one that builds further customer loyalty as we continue to deliver more value.
The repositioning of our Institutional business, which is a big priority for us is progressing well, as demonstrated by strong sales growth and margin leverage within that segment. Healthcare & Life Sciences organic sales growth strengthened, while operating income remained under pressure, near-term at least as we continue to invest in growth and transformation. There are two very different businesses and stories within that segment. In Healthcare, we continue to take actions to improve profitability, whereas in Life Sciences, we're making further investments as we add capacity and capabilities in Purolite to capitalize on very attractive and profitable long-term growth opportunities.
While we continued investing in our long-term capabilities and in digital technology, we also continued to make solid progress in SG&A productivity. The combination of improved gross margins and better operational productivity led to strong organic operating income growth of 19%, up from 10% in the fourth quarter last year. Our adjusted earnings per share growth improved to 7%, which includes a 13% headwind from FX and interest.
In summary, we started the year exactly the way we wanted with strong top and bottom line momentum, despite the challenging environment. Looking ahead, we anticipate inflation to remain high for the foreseeable future, interest rates to have a strong impact on global demand and continued geopolitical tensions. Although none of this is new, the good news is that we are very well-positioned to win in this environment.
Over the last few years, our expertise grew as we focused on supporting our team and developing innovative solutions. Our customer retention rates remain high, as we protected them from supply shortages. Our margin started to recover and our organic operating income accelerated as we drove pricing in thoughtful ways, while increasing customer value. And now as macro trends are softening, we will continue to accelerate our shift to offense, by accelerating new business, by executing extremely well and by driving productivity improvements and continuing to invest in our major growth engines to drive profitable growth. This will ensure we deliver stronger sequential earnings performance, exactly as we've indicated during our previous calls.
With this, we expect adjusted earnings growth in the second quarter to be in the plus 5% to plus 14% range and to end the year as expected with adjusted earnings growth in the fourth quarter that reaches low double digits. And finally, we will remain good stewards of capital by continuing to invest in the business, increasing our dividend, reducing our leverage and returning cash to shareholders as we've always done. And most importantly, with the best team, science and capabilities in the industry, we are well prepared to grow our share of these high quality $152 billion growth market. I believe our future has never looked brighter. I look forward to your questions.